[Application of selective acetylcholine-sensitive K+ -channel blockade as a therapeutic strategy for atrial fibrillation].
Hashimoto
Norio
N
Nissan Chemical America Corporation, Houston, TX 77042, USA. norio.hashimoto@nissanchem-usa.com
D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001514:Bee Venoms / Q000494:pharmacology / Q000627:therapeutic use; D001578:Benzopyrans / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D004558:Electric Stimulation; D006325:Heart Atria / Q000503:physiopathology; D006801:Humans; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels / Q000378:metabolism / Q000502:physiology; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D001514:Bee Venoms; D001578:Benzopyrans; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; C449401:NIP 141; C529784:NIP 151; D026902:Potassium Channel Blockers; C029738:tertiapin; D000109:Acetylcholine